Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AbCellera Biologics Inc. (ABCL : NSDQ)
 
 • Company Description   
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

Number of Employees: 596

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.01 Daily Weekly Monthly
20 Day Moving Average: 6,129,922 shares
Shares Outstanding: 298.42 (millions)
Market Capitalization: $1,196.68 (millions)
Beta: 0.62
52 Week High: $4.40
52 Week Low: $1.89
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 25.31% 19.65%
12 Week 65.70% 39.84%
Year To Date 36.86% 28.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
150 W 4TH AVENUE
-
VANCOUVER,A1 V5Y 1G6
CAN
ph: 604-559-9005
fax: -
ir@abcellera.com http://www.abcellera.com
 
 • General Corporate Information   
Officers
Carl L. G. Hansen - Chief Executive Officer and Director
Veronique Lecault - Chief Operating Officer and Director
Andrew Booth - Chief Financial Officer
Michael Hayden - Director
John S. Montalbano - Director

Peer Information
AbCellera Biologics Inc. (CORR.)
AbCellera Biologics Inc. (RSPI)
AbCellera Biologics Inc. (CGXP)
AbCellera Biologics Inc. (BGEN)
AbCellera Biologics Inc. (GTBP)
AbCellera Biologics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00288U106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 298.42
Most Recent Split Date: (:1)
Beta: 0.62
Market Capitalization: $1,196.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.67 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.17
Price/Cash Flow: -
Price / Sales: 51.77
EPS Growth
vs. Year Ago Period: -7.14%
vs. Previous Quarter: -36.36%
Sales Growth
vs. Year Ago Period: -57.45%
vs. Previous Quarter: -16.14%
ROE
06/30/25 - -
03/31/25 - -15.98
12/31/24 - -14.89
ROA
06/30/25 - -
03/31/25 - -12.38
12/31/24 - -11.57
Current Ratio
06/30/25 - -
03/31/25 - 10.15
12/31/24 - 9.81
Quick Ratio
06/30/25 - -
03/31/25 - 10.15
12/31/24 - 9.81
Operating Margin
06/30/25 - -
03/31/25 - -737.56
12/31/24 - -564.81
Net Margin
06/30/25 - -
03/31/25 - -737.56
12/31/24 - -564.81
Pre-Tax Margin
06/30/25 - -
03/31/25 - -911.23
12/31/24 - -695.02
Book Value
06/30/25 - -
03/31/25 - 3.43
12/31/24 - 3.58
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©